CKD-506 treatment significantly reduced serum levels of IL-10, IL-15, IL-17A, TNF-α, and IL-22 and significantly increased serum level of TGF-β1 in a murine model of SLE. This evidence concerns the gene TGFB1 and systemic lupus erythematosus.